News

PERNIX THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER

Morristown, New Jersey, June 23, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer. Mr. Patel brings to Pernix over 15 years of investment banking, institutional investment and public policy experience....
Read more

PERNIX signs agreement to acquire TREXIMET® Tablets for Migraine from GSK

Morristown, NJ, May 14, 2014 – Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has signed an agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine...
Read more

PERNIX THERAPEUTICS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS

MORRISTOWN, NJ, May 12, 2014 – Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2014. Business Update The first quarter of 2014 continued to be a work in progress as Pernix took further...
Read more

PERNIX THERAPEUTICS APPOINTS TASOS KONIDARIS TO ITS BOARD OF DIRECTORS

Morristown, NJ, April 28, 2014 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Tasos Konidaris as a non-executive Director and as Chairman of the Audit Committee. Mr. Konidaris has served as Senior Vice President and Chief Financial Officer of Ikaria, Inc., a...
Read more